Clinical Trials Logo

EGFR Amplification clinical trials

View clinical trials related to EGFR Amplification.

Filter by:
  • None
  • Page 1

NCT ID: NCT06022276 Recruiting - Solid Tumor Clinical Trials

Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

To evaluate the efficacy and safety of nimotuzumab in the treatment of EGFR-amplified advanced pan solid tumors (Lung/Esophageal/Gastric/Pancreatic /Colorectal / Head and neck Cervical).

NCT ID: NCT05290441 Recruiting - COVID-19 Pneumonia Clinical Trials

Evaluation of Postmortem Pulmonary Interstitial Fibrosis Severity and EGFR Positivity in Covid-19 Pneumonia

Start date: August 15, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to examine the relationship between the severity of fibrosis in the lung tissue and EGFR positivity in patients who died due to covid-19 pneumonia, with the demographic characteristics, comorbidities, biochemistry values, treatments they received, and radiological appearances. Transthoracic tru-cut biopsy will be performed on patients who have died in the intensive care unit with the diagnosis of Covid 19 pneumonia. EGFR positivity will be evaluated in the material taken. The relationship between the severity of fibrosis and the demographic data of the patients, the drugs used and their radiological appearances will be analyzed statistically.

NCT ID: NCT04429542 Recruiting - Colorectal Cancer Clinical Trials

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

Start date: June 1, 2020
Phase: Phase 1
Study type: Interventional

The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

NCT ID: NCT03618667 Completed - Glioblastoma, Adult Clinical Trials

GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification

Start date: January 22, 2018
Phase: Phase 2
Study type: Interventional

This study is a phase 2 trial of GC1118, an EGFR monoclonal antibody, for recurrent glioblastoma patients who were treated with standard concurrent chemoradiation.